RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)

Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, low-dose corticosteroids, and Hydroxychloroquine (which has now been done). A World Health Organization (WHO) expert group issued broadly similar advice. These groups also advised that other treatments will soon emerge that require evaluation.

Eligibility and randomisation: This protocol describes a randomised trial among patients hospitalised for COVID-19. All eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital. The study is subdivided into several parts, according to whether participants are children or adults, and by geographic area. The study is dynamic, and treatments are added and removed as results and suitable treatments become available. The parts in this version of the protocol (which should be checked and confirmed as the current latest version) are as follows:

Part A (Children only): No additional treatment vs corticosteroids vs intravenous immunoglobulin. See below for possible second randomisation in the children with PIMS-TS).

Part A (UK adults ≥18 years old only): Early phase assessment - Dimethyl fumarate vs no additional treatment, and additional information on efficacy and safety collected.
Part B: discontinued in version 16.0.
Part C: discontinued in V15.0.
Part D (UK [age ≥2 years] and India [age ≥18 years] only): In a factorial design, baricitinib vs no additional treatment.
Part E (non-UK countries; adults ≥18 years old with hypoxia only: In a factorial design, high-dose corticosteroids vs no additional treatment

Part F (adults ≥18 years): In a factorial design, empagliflozin vs no additional treatment

The study allows a subsequent randomisation for children with PIMS-TS (hyper-inflammatory state associated with COVID-19): No additional treatment vs tocilizumab vs anakinra. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.

RECOVERY will also assess interventions for which additional information is required to determine whether they are considered for large-scale assessment as their potential to improve outcomes in COVID-19 is uncertain. Hence, for some patients the main randomisation part A will include an Early Phase Assessment arm in which patients may be randomised to receive dimethyl fumarate and additional information on efficacy and safety collected.

Adaptive design: The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The most important task for the DMC will be to assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform
the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. Regardless, follow-up will continue for all randomised participants, including those previously assigned to trial arms that are modified or ceased. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.

**Outcomes:** The main outcomes will be death, discharge, need for ventilation and need for renal replacement therapy. For the main analyses, follow-up will be censored at 28 days after randomisation. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases where available (such as those managed by NHS Digital and equivalent organisations in the devolved nations).

**Simplicity of procedures:** To facilitate collaboration, even in hospitals that suddenly become overloaded, patient enrolment (via the internet) and all other trial procedures are greatly streamlined. Informed consent is simple and data entry is minimal. Randomisation via the internet is simple and quick, at the end of which the allocated treatment is displayed on the screen and can be printed or downloaded. Key follow-up information is recorded at a single timepoint and may be ascertained by contacting participants in person, by phone or electronically, or by review of medical records and databases.

**Data to be recorded:** At randomisation, information will be collected on the identity of the randomising clinician and of the patient, age, sex, major co-morbidity, pregnancy, COVID-19 onset date and severity, and any contraindications to the study treatments. The main outcomes will be death (with date and probable cause), discharge (with date), need for ventilation (with number of days recorded) and need for renal replacement therapy. Reminders will be sent if outcome data have not been recorded by 28 days after randomisation. Suspected Unexpected Serious Adverse Reactions (SUSARs) to one of the study medications (e.g., Stevens-Johnson syndrome, anaphylaxis, aplastic anaemia) will be collected and reported in an expedited fashion. Other adverse events will not be recorded but may be available through linkage to medical databases.

**Numbers to be randomised:** The larger the number randomised the more accurate the results will be, but the numbers that can be randomised will depend critically on how large the epidemic becomes. If substantial numbers are hospitalised in the participating centres then it may be possible to randomise several thousand with mild disease and a few thousand with severe disease, but realistic, appropriate sample sizes could not be estimated at the start of the trial.

**Heterogeneity between populations:** If sufficient numbers are studied, it may be possible to generate reliable evidence in certain patient groups (e.g. those with major co-morbidity or who are older). To this end, data from this study may be combined with data from other trials of treatments for COVID-19, such as those being planned by the WHO.

**Add-on studies:** Particular countries or groups of hospitals, may well want to collaborate in adding further measurements or observations, such as serial virology, serial blood gases or chemistry, serial lung imaging, or serial documentation of other aspects of disease status. While well-organised additional research studies of the natural history of the disease or of the effects of the trial treatments could well be valuable (although the lack of placebo control may bias the assessment of subjective side-effects, such as gastro-intestinal problems), they are not core requirements.
To enquire about the trial, contact the RECOVERY Central Coordinating Office
Nuffield Department of Population Health, Richard Doll Building, Old Road Campus,
Roosevelt Drive, Oxford OX3 7LF, United Kingdom
Tel: 0800 1385451 | E-mail: recoverytrial@ndph.ox.ac.uk | Website: www.recoverytrial.net
To enquire about the trial outside of the UK, contact the relevant Clinical Trial Units
To RANDOMISE a patient, visit: www.recoverytrial.net
1 BACKGROUND AND RATIONALE .................................................................................. 5
  1.1 SETTING .................................................................................................................. 5
  1.2 TREATMENT OPTIONS .......................................................................................... 5
  1.3 DESIGN CONSIDERATIONS ................................................................................... 7
  1.4 POTENTIAL FOR EFFECTIVE TREATMENTS TO BECOME AVAILABLE ............. 7
  1.5 EARLY PHASE ASSESSMENTS .............................................................................. 8

2 DESIGN AND PROCEDURES ..................................................................................... 8
  2.1 ELIGIBILITY ............................................................................................................ 8
  2.2 CONSENT ............................................................................................................... 9
  2.3 BASELINE INFORMATION .................................................................................... 10
  2.4 MAIN RANDOMISATION ....................................................................................... 10
  2.5 SECOND RANDOMISATION FOR CHILDREN WITH PROGRESSIVE PIMS-TS ... 12
  2.6 ADMINISTRATION OF ALLOCATED TREATMENT ............................................ 13
  2.7 COLLECTING FOLLOW-UP INFORMATION ....................................................... 13
  2.8 DURATION OF FOLLOW-UP ................................................................................ 15
  2.9 WITHDRAWAL OF CONSENT .............................................................................. 15

3 STATISTICAL ANALYSIS ............................................................................................ 16
  3.1 OUTCOMES ......................................................................................................... 16
  3.2 METHODS OF ANALYSIS .................................................................................... 16
  3.3 CHILDREN ........................................................................................................... 17
  3.4 EARLY PHASE ASSESSMENTS ............................................................................ 17

4 DATA AND SAFETY MONITORING ........................................................................... 18
  4.1 RECORDING SUSPECTED SERIOUS ADVERSE REACTIONS ......................... 18
  4.2 CENTRAL ASSESSMENT AND ONWARD REPORTING OF SUSARs ............. 18
  4.3 RECORDING OTHER ADVERSE EVENTS ......................................................... 19
  4.4 ROLE OF THE DATA MONITORING COMMITTEE (DMC) .............................. 19
  4.5 BLINING ............................................................................................................... 19

5 QUALITY MANAGEMENT ........................................................................................... 20
  5.1 QUALITY BY DESIGN PRINCIPLES ................................................................. 20
  5.2 TRAINING AND MONITORING .......................................................................... 20
  5.3 DATA MANAGEMENT .......................................................................................... 21
  5.4 SOURCE DOCUMENTS AND ARCHIVING ....................................................... 21

6 OPERATIONAL AND ADMINISTRATIVE DETAILS .................................................... 21
  6.1 SPONSOR AND COORDINATION ..................................................................... 21
  6.2 FUNDING ............................................................................................................ 21
  6.3 INDEMNITY ......................................................................................................... 22
  6.4 LOCAL CLINICAL CENTRES .............................................................................. 22
  6.5 SUPPLY OF STUDY TREATMENTS .................................................................. 22
  6.6 END OF TRIAL .................................................................................................... 22
  6.7 PUBLICATIONS AND REPORTS ...................................................................... 22
  6.8 SUBSTUDIES ...................................................................................................... 23

7 VERSION HISTORY .................................................................................................... 24

8 APPENDICES .............................................................................................................. 26
  8.1 APPENDIX 1: INFORMATION ABOUT THE TREATMENT ARMS ................ 26
  8.2 APPENDIX 2: DRUG SPECIFIC CONTRAINDICATIONS AND CAUTIONS .... 29
  8.3 APPENDIX 3: PAEDIATRIC DOSING INFORMATION ........................................... 31
  8.4 APPENDIX 4: USE OF IMPS IN PREGNANT AND BREASTFEEDING WOMEN 33
  8.5 APPENDIX 5: EARLY PHASE ASSESSMENT DETAILS ..................................... 35
  8.6 APPENDIX 6: ORGANISATIONAL STRUCTURE AND RESPONSIBILITIES .... 36

9 REFERENCES ............................................................................................................... 38
10 CONTACT DETAILS ................................................................................................. 41
1 BACKGROUND AND RATIONALE

1.1 Setting
In 2019 a novel coronavirus-disease (COVID-19) emerged in Wuhan, China. A month later the Chinese Center for Disease Control and Prevention identified a new beta-coronavirus (SARS coronavirus 2, or SARS-CoV-2) as the aetiological agent. The clinical manifestations of COVID-19 range from asymptomatic infection or mild, transient symptoms to severe viral pneumonia with respiratory failure. As many patients do not progress to severe disease the overall case fatality rate per infected individual is low, but hospitals in areas with significant community transmission have experienced a major increase in the number of hospitalised pneumonia patients, and the frequency of severe disease in hospitalised patients can be as high as 30%. The progression from prodrome (usually fever, fatigue and cough) to severe pneumonia requiring oxygen support or mechanical ventilation often takes one to two weeks after the onset of symptoms. The kinetics of viral replication in the respiratory tract are not well characterized, but this relatively slow progression provides a potential time window in which antiviral therapies could influence the course of disease. In May 2020 a new COVID-associated inflammatory syndrome in children was identified, Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS). A rapid NHS England-led consensus process identified the need to evaluate corticosteroids and intravenous immunoglobulin (IVIg) as initial therapies in PIMS-TS, and confirmed tocilizumab as one of the biological anti-inflammatory agents to be evaluated as a second line therapy.

1.2 Treatment Options

1.2.1 Main randomisation
This protocol allows reliable assessment of the effects of multiple different treatments (including re-purposed and novel drugs) on major outcomes in COVID-19. All patients will receive usual care for the participating hospital.

Randomisation part A: Eligible patients may be randomly allocated between the following treatment arms:

- No additional treatment
- Dimethyl fumarate (UK adults ≥18 years old only; early phase assessment)
- Corticosteroids (children ≤44 weeks gestational age with COVID-19 pneumonia, or >44 weeks gestational age with PIMS-TS only)
- Intravenous immunoglobulin (children >44 weeks gestational age with PIMS-TS only)
Randomisation part D (UK and India only): Simultaneously, eligible patients will be randomly allocated between the following treatment arms:

- No additional treatment
- Baricitinib (adults, and children ≥2 years old with COVID-19 pneumonia [UK and India only])

Randomisation part E (adults ≥18 years old with hypoxia only [non-UK countries only]):
Simultaneously, eligible patients will be randomly allocated between the following treatment arms:

- No additional treatment\textsuperscript{b}
- High-dose dexamethasone

Randomisation part F (adults ≥18 years old):
Simultaneously, eligible patients will be randomly allocated between the following treatment arms:

- No additional treatment
- Empagliflozin

1.2.2 Second randomisation for children with PIMS-TS
Severe COVID-19 is associated with release of pro-inflammatory cytokines, such as IL-1, IL-6 and TNFα, and other markers of systemic inflammation including ferritin and C-reactive protein.\textsuperscript{6,8}

Children (at least 1 year old) with PIMS-TS (as evidenced by an exaggerated inflammatory state) may undergo an optional second randomisation between the following treatment arms:

- No additional treatment
- Tocilizumab (children ≥1 <18 years old only)
- Anakinra (children ≥1 <18 years old only)

1.2.3 Modifications to the number of treatment arms
Other arms can be added to the first or second randomisation if evidence emerges that there are suitable candidate therapeutics. Conversely, in some patient populations, not all trial

\textsuperscript{a} Main randomisation part B was discontinued in V16.0 and part C in V15.0 of the protocol respectively.
\textsuperscript{b} Usual care in hypoxic patients is expected to include low dose (6mg daily) dexamethasone

ISRCTN50189673
EudraCT 2020-001113-21
arms are appropriate (e.g. due to contraindications based on co-morbid conditions or concomitant medication); in some hospitals or countries, not all treatment arms will be available (e.g. due to manufacturing and supply shortages); and at some times, not all treatment arms will be active (e.g. due to lack of relevant approvals and contractual agreements). The Trial Steering Committee may elect to pause one or more of the arms in order to increase trial efficiency during a fluctuating epidemic. In any of these situations, randomisation will be between fewer arms. Depending on the availability and suitability of treatments, it may be allowed for participants to be randomised in only one or two parts (A, D or F [UK], D, E or F [ex-UK]) of the main randomisation.

1.3 Design Considerations
The RECOVERY Protocol describes an overarching trial design to provide reliable evidence on the efficacy of candidate therapies for suspected or confirmed COVID-19 infection in hospitalised patients receiving usual standard of care.

In early 2020, when the trial first started, there were no known treatments for COVID-19. The anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched at some points in time, with around 10% requiring hospitalisation. In this situation, even treatments with only a moderate impact on survival or on hospital resources could be worthwhile. Therefore, the focus of RECOVERY is the impact of candidate treatments on mortality and on the need for hospitalisation or ventilation.

Critically, the trial is designed to minimise the burden on front-line hospital staff working within an overstretched care system during a major epidemic. Eligibility criteria are therefore simple and trial processes (including paperwork) are minimised.

The protocol is deliberately flexible so that it is suitable for a wide range of settings, allowing:
- a broad range of patients to be enrolled in large numbers;
- randomisation between only those treatment arms that are both available at the hospital and not believed by the enrolling doctor to be contraindicated (e.g. by particular co-morbid conditions or concomitant medications);
- treatment arms to be added or removed according to the emerging evidence; and
- additional substudies may be added to provide more detailed information on side effects or sub-categorisation of patient types but these are not the primary objective and are not required for participation.

In a cohort of 191 hospitalised COVID-19 patients with a completed outcome, the median time from illness onset to discharge was 22.0 days (IQR 18.0–25.0) and the median time to death was 18.5 days (15.0–22.0). Thirty-two patients (17%) required invasive mechanical ventilation and the median time from onset to mechanical ventilation was 14.5 days. Therefore, early endpoint assessment, such as 28 days after randomisation, is likely to provide largely complete outcome data and will permit early assessment of treatment efficacy and safety.9

1.4 Potential for effective treatments to become available

In early 2020, when the trial first started, there were no known treatments for COVID-19. However, over time, effective treatments may become available, typically as the result of
reliable information from randomised trials (including from this study). For example, in June 2020, results from the RECOVERY trial showed that dexamethasone reduces the mortality in COVID-19 patients requiring mechanical ventilation or oxygen. In response, many clinical guidelines now recommend the use of dexamethasone as standard of care for these types of patients.

The RECOVERY trial randomises eligible participant to usual standard of care for the local hospital alone vs usual standard of care plus one or more additional study treatments. Over time, it is expected that usual standard of care alone will evolve. Thus randomisation will always be relevant to the current clinical situation and the incremental effects of the study treatments will be appropriately assessed.

1.5 Early phase assessments

In the UK, the COVID-19 Therapeutics Advisory Panel (CTAP\textsuperscript{c}) may propose that RECOVERY assesses interventions for which additional information is required before they are considered for large-scale assessment of the impact on mortality. Such assessments will be tailored to the uncertainty specific to the intervention and typically be conducted at a subset of sites among a smaller group of participants before the results are reviewed and a decision made whether to include them in the main trial.

2 DESIGN AND PROCEDURES

2.1 Eligibility

Patients are eligible for the study if all of the following are true:

(i) **Hospitalised**

(ii) **SARS-CoV-2 infection associated disease (clinically suspected or laboratory confirmed)**

In general, SARS-CoV-2 disease should be suspected when a patient presents with:

a) typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and

b) compatible chest X-ray findings (consolidation or ground-glass shadowing); and

c) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza).

However, the diagnosis remains a clinical one based on the opinion of the managing doctor.

A small number of children (aged <18 years) present with atypical features, including a hyperinflammatory state and evidence of single or multi-organ dysfunction (called Paediatric Multisystem Inflammatory Syndrome temporally associated with COVID-19 [PIMS-TS]). Some do not have significant lung involvement.

(iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

In addition, if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Appendix 2; section 8.2 and Appendix 3; section 8.3 for children) or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.

In some locations, children (aged <18 years) will not be recruited, to comply with local and national regulatory approvals (see Section 8.3).

2.2 Consent

Informed consent should be obtained from each patient 16 years and over before enrolment into the study. However, if the patient lacks capacity to give consent due to the severity of their medical condition (e.g. acute respiratory failure or need for immediate ventilation) or prior disease, then consent may be obtained from a relative acting as the patient’s legally designated representative or – if a suitable relative is not available after reasonable efforts to locate one – an independent doctor. Further consent will then be sought with the patient if they recover sufficiently. For children aged <16 years old consent will be sought from their parents or legal guardian. Where possible, children aged between 10-15 years old will also be asked for assent. Children aged ≥16 years old will asked for consent as for adults. Witnessed consent may be obtained over the telephone or web video link if hospital visiting rules or parental infection mean a parent/guardian cannot be physically present.

Due to the poor outcomes in COVID-19 patients who require ventilation (>90% mortality in one cohort⁹), patients who lack capacity to consent due to severe disease (e.g. needs ventilation), and for whom a relative to act as the legally designated representative is not available, randomisation and consequent treatment will proceed with consent provided by a treating clinician (independent of the clinician seeking to enrol the patient) who will act as the legally designated representative (if allowed by local regulations). Consent will then be obtained from the patient’s personal legally designated representative (or directly from the patient if they recover promptly) at the earliest opportunity.

In the UK, participants’ GPs will be informed of their participation using routine clinical communications (e.g. discharge summaries). If any other relevant information arises during the trial, this may also be sent to GPs.

---

2.3 Baseline information

The following information will be recorded on the web-based form by the attending clinician or delegate:

- Patient details (e.g. name or initials [depending on privacy requirements], NHS/CHI number [UK only] or medical records number, date of birth, sex)
- Clinician details (e.g. name)
- COVID-19 symptom onset date
- COVID-19 severity as assessed by need for supplemental oxygen, non-invasive ventilation or invasive mechanical ventilation/extracorporeal membrane oxygenation (ECMO)
- Oxygen saturations on air (if available), and S/F94 ratio (if participating in early phase assessment; see Section 2.7.1)
- Latest routine measurement of creatinine, C-reactive protein, and D-dimer (if available)
- Major co-morbidity (e.g. heart disease, diabetes, chronic lung disease) and pregnancy (including pregnancy test result in all women of child-bearing potential)
- Use of relevant medications (corticosteroids, remdesivir, antiplatelet and anticoagulant therapy)
- Date of hospitalisation
- Contraindication to the study treatment regimens (in the opinion of the attending clinician)
- Name of person completing the form

The person completing the form will then be asked to confirm that they wish to randomise the patient and will then be required to enter their name and e-mail address.

2.4 Main randomisation

In addition to receiving usual care, eligible patients will be allocated using a central web-based randomisation service (without stratification or minimisation). From version 6.0 of the protocol, a factorial design will be used such that eligible patients may be randomised to one or more of the treatment arms in Randomisations A, D, E and F (depending on location). From version 12.1 of the protocol, children may be recruited into the trial even if there are no main randomisation treatments which are both available and suitable provided they meet the criteria for inclusion in the second randomisation, per section 2.5. They will not be allocated to a main randomisation group, but will be potentially eligible for the second randomisation between tocilizumab, anakinra and control.

---

* A woman of childbearing potential is defined as a post-menarchal pre-menopausal female capable of becoming pregnant. This includes women on oral, injectable, or mechanical contraception; women who are single; women whose male partners have been vasectomized or whose male partners have received or are utilizing mechanical contraceptive devices.
2.4.1 Main randomisation part A:
Eligible patients may be randomised to one of the arms listed below. The doses in this section are for adults. Please see Appendix 3 for paediatric dosing. Study treatments do not need to be continued after discharge from hospital.

- No additional treatment

- Dimethyl fumarate: 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total). (Adults ≥18 years old only, excluding those on ECMO.) If 240 mg every 12 hours cannot be tolerated, the dose may be reduced.

- Corticosteroid (in children ≤44 weeks gestational age, or >44 weeks gestational age with PIMS-TS only): see Appendix 3.

- Intravenous immunoglobulin (in children >44 weeks gestational age with PIMS-TS only): see Appendices 2 and 3 for dose, contraindications and monitoring information.

For randomisation part A, the randomisation program will allocate patients in a ratio of 1:1 between the no additional treatment arm and each of the other arms available. If one or more of the active drug treatments is not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then this fact will be recorded via the web-based form prior to randomisation; random allocation will then be between the remaining arms. If no treatments are both available and suitable, then it may be possible to only be randomised in part B (UK only) and/or part D (UK only) and/or part E (ex-UK only) and/or part F.

2.4.2 Main randomisation part D [adults (UK and India only), and children with COVID-19 pneumonia aged ≥2 years only (UK only)]:
Eligible patients may be randomised to one of the arms listed below.

- No additional treatment

- Baricitinib 4 mg once daily by mouth or nasogastric tube for 10 days in total.

The randomisation program will allocate patients in a ratio of 1:1 between the arms being evaluated in part D of the main randomisation.

2.4.3 Main randomisation part E [adults with hypoxia; non-UK countries only]:
Adult patients enrolled in the RECOVERY trial and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations <92% on room air) may be randomised to one of the arms listed below.

- No additional treatment

---

1 Treatment should be discontinued at 10 days or on discharge from hospital if sooner
- High-dose corticosteroids: dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.\textsuperscript{g}

The randomisation program will allocate patients in a ratio of 1:1 between the arms being evaluated in part E of the main randomisation.

2.4.4 Main randomisation part F [adults ≥18 years old only]:
Adult patients enrolled in the RECOVERY trial may be randomised to one of the arms listed below.

- No additional treatment

- Empagliflozin 10 mg once daily by mouth for 28 days (or until discharge, if earlier).

The randomisation program will allocate patients in a ratio of 1:1 between the arms being evaluated in part F of the main randomisation.

2.5 Second randomisation for children with progressive PIMS-TS
Children (≥1 year old) enrolled in the RECOVERY trial and with clinical evidence of a hyper-inflammatory state may be considered for a second randomisation if they meet the following criteria:

(i) Recruited into the RECOVERY trial no more than 21 days ago\textsuperscript{h}
(ii) Clinical evidence of PIMS-TS:
   a. significant systemic disease with persistent pyrexia, with or without evidence of respiratory involvement\textsuperscript{i}; and
   b. C-reactive protein ≥75 mg/L
(iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in this aspect of the RECOVERY trial.

Note: Pregnancy and breastfeeding are not specific exclusion criteria.)

Note: Participants may undergo this second randomisation at any point after being first randomised, provided they meet the above criteria, and thus may receive up to two study treatments (one from Main randomisation part A plus one from the second randomisation). For some participants the second randomisation may be immediately after the first but for others it may occur a few hours or days later, if and when they deteriorate.

\textsuperscript{g} Pregnant women should receive either prednisolone (130 mg) orally or hydrocortisone (540 mg in four divided doses) intravenously or methylprednisolone (100 mg) intravenously for five days, followed by either prednisolone (65 mg) orally or hydrocortisone (270 mg in four divided doses) intravenously or methylprednisolone (50 mg) intravenously for five days.

\textsuperscript{h} Children recruited into RECOVERY for whom no main randomisation treatment are both available and suitable (see section 2.4) should undergo this second randomisation as soon as possible after recruitment.

\textsuperscript{i} A small number of children (age <18 years) present with atypical features, including a hyperinflammatory state and evidence of single or multi-organ dysfunction. Some do not have significant lung involvement. (see: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf)
The following information will be recorded (on the web-based form) by the attending clinician or delegate:

- Patient details (e.g. name or initials, NHS/CHI number [UK only] or medical records number, date of birth, sex)
- Clinician details (e.g. name)
- COVID-19 severity as assessed by need for supplemental oxygen or ventilation/ECMO
- Markers of progressive COVID-19 (including oxygen saturation, C-reactive protein)
- Contraindication to the study drug treatments (in the opinion of the attending clinician)
- Name of person completing the form

The person completing the form will then be asked to confirm that they wish to randomise the patient and will then be required to enter their own name and e-mail address.

Eligible participants may be randomised between the following treatment arms (see Appendix 3 for dose information):

- **Tocilizumab** by intravenous infusion  
  Tocilizumab should be given as a single intravenous infusion over 60 minutes in 100ml sodium chloride 0.9%. A second dose may be given ≥12 and <24 hours later if, in the opinion of the attending clinician, the patient’s condition has not improved.

- **Anakinra** subcutaneously or intravenously once daily for 7 days or discharge (if sooner).  
  NB Anakinra will be excluded from the randomisation of children <10 kg in weight.

- **No additional treatment**

The randomisation program will allocate patients in a ratio of 2:2:1 (tocilizumab:anakinra:no additional treatment) between the arms being evaluated in the second randomisation. Participants should receive standard management (including blood tests such as liver function tests and full blood count) according to their clinical need.

2.6 Administration of allocated treatment

The details of the allocated study treatments will be displayed on the screen and can be printed or downloaded. The hospital clinicians are responsible for prescription and administration of the allocated treatments. The patient’s own doctors are free to modify or stop study treatments if they feel it is in the best interests of the patient without the need for the patient to withdraw from the study (see section 2.9). This study is being conducted within hospitals. Therefore use of medication will be subject to standard medication reviews (typically within 48 hours of enrolment) which will guide modifications to both the study treatment and use of concomitant medication (e.g. in the case of potential drug interactions).

2.7 Collecting follow-up information

The following information will be ascertained at the time of death or discharge or at 28 days after first randomisation (whichever is sooner):

- Vital status (alive / dead, with date and presumed cause of death, if appropriate)
- Hospitalisation status (inpatient / discharged, with date of discharge, if appropriate)
• SARS-CoV-2 test result
• Use of ventilation (with days of use and type, if appropriate)
• Use of renal dialysis or haemofiltration
• Documented new major cardiac arrhythmia (including atrial and ventricular arrhythmias)
• Major bleeding (defined as intracranial bleeding or bleeding requiring transfusion, endoscopy, surgery, or vasoactive drugs)
• Thrombotic event, defined as either (i) acute pulmonary embolism; (ii) deep vein thrombosis; (iii) ischaemic stroke; (iv) myocardial infarction; or (v) systemic arterial embolism.
• Non-coronavirus infection, categorised by site and putative organism (virus, bacteria, fungus, other)
• Use of any medications included in the RECOVERY trial protocol (including drugs in the same class) or other purported COVID-19 treatments (e.g. remdesivir)
• Participation in other randomised trials of interventions (vaccines or treatments) for COVID-19.
• Metabolic complications: Ketoacidosis; hyperglycaemic hyperosmolar state; hyperglycaemia requiring new use of insulin; severe hypoglycaemia (defined as hypoglycaemia causing reduced conscious level requiring another person to help recover)
• Laboratory results: highest creatinine recorded during admission
• Additional information including results of routine tests (including full blood count, coagulation and inflammatory markers, cardiac biomarkers, electro- and echo-cardiograms), other treatments given, length of stay in paediatric high-dependency/intensive care and a paediatric-appropriate frailty score will be collected for children in the UK. This information will be obtained and entered into the web-based IT system by a member of the hospital clinical or research staff. Some of this information may be collected at about 6 weeks after randomisation (at the time of a routine hospital follow-up appointment in-person or by telephone) ideally by someone unaware of treatment allocation.
• At some locations, electrocardiograms done as part of routine care of adult participants will also be collected.

Follow-up information is to be collected on all study participants, irrespective of whether or not they complete the scheduled course of allocated study treatment. Study staff will seek follow-up information through various means including medical staff, reviewing information from medical notes, routine healthcare systems, and registries.

For all randomised participants, vital status (alive / dead, with date and presumed cause of death, if appropriate) is to be ascertained at 28 days after first randomisation. This may be achieved through linkage to routine death registration data (e.g. in the UK) or through direct contact with the participant, their relatives, or medical staff and completion of an additional follow-up form.

2.7.1 Additional procedures for participants in early phase assessments
2.7.1.1 Dimethyl fumarate vs. Usual Care

In addition, the following information will be collected for participants in the early phase assessment of dimethyl fumarate (see Appendix 5 for further details), including participants allocated usual care in this comparison:

- S/F<sub>94</sub> ratio on days 3, 5 and 10 (unless discharged sooner)
- WHO Ordinal Score<sup>10</sup> each day after randomisation until day 10 (or discharge if sooner)
- Blood C-reactive protein, creatinine and alanine (or aspartate) transaminase on days 3, 5 and 10 (unless discharged sooner)
- Incidence and severity of flushing and gastrointestinal symptoms
- Reasons for stopping dimethyl fumarate

2.8 Duration of follow-up

All randomised participants are to be followed up until death, discharge from hospital or 28 days after randomisation (whichever is sooner). It is recognised that in the setting of this trial, there may be some variability in exactly how many days after randomisation, information on disease status is collected. This is acceptable and will be taken account of in the analyses and interpretation of results, the principle being that some information about post-randomisation disease status is better than none.

In the UK, longer term (up to 10 years) follow-up will be sought through linkage to electronic healthcare records and medical databases including those held by NHS Digital, Public Health England and equivalent bodies, and to relevant research databases (e.g. UK Biobank, Genomics England). Outside the UK, due to the absence of electronic health data linkage, additional follow-up will be conducted at 3 and 6 months after first randomisation by telephone or in person (at a clinic) in order to collect information on mortality (including date and cause) and re-admission to hospital (including date[s] and primary reason[s]). This information will be captured on a web-based case report form.

2.9 Withdrawal of consent

A decision by a participant (or their parent/guardian) that they no longer wish to continue receiving study treatment should not be considered to be a withdrawal of consent for follow-up. However, participants (or their parent/guardian) are free to withdraw consent for some or all aspects of the study at any time if they wish to do so. In accordance with regulatory guidance, de-identified data that have already been collected and incorporated in the study database will continue to be used (and any identifiable data will be destroyed).

For participants who lack capacity, if their legal representative withdraws consent for treatment or methods of follow-up then these activities would cease.
3 STATISTICAL ANALYSIS

All analyses for reports, presentations and publications will be prepared by the coordinating centre at the Nuffield Department of Population Health, University of Oxford. A more detailed statistical analysis plan will be developed by the investigators and published on the study website whilst still blind to any analyses of aggregated data on study outcomes by treatment allocation.

3.1 Outcomes

For each pairwise comparison with the ‘no additional treatment’ arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality at 28 days after randomisation (with subsidiary analyses of cause of death and of death at various timepoints following discharge).

The secondary objectives are to assess the effects of study treatments on duration of hospital stay; and, among patients not on invasive mechanical ventilation at baseline, the composite endpoint of death or need for invasive mechanical ventilation or ECMO.

Other objectives include the assessment of the effects of study treatments on the need for any ventilation (and duration of invasive mechanical ventilation), acute kidney injury and renal replacement therapy, and thrombotic events. Safety outcomes include bleeding, new major cardiac arrhythmias, metabolic complications (ketoadsisis, hyperglycaemic hyperosmolar state, hyperglycaemia requiring new use of insulin, severe hypoglycaemia) and (assessed at 72 hours after randomization among participants in main randomization part B only) sudden worsening in respiratory status, severe allergic reaction, significant fever, sudden hypotension and clinical haemolysis (which were collected until 15 January 2021 when the DMC recommended they were no longer required).

Study outcomes will be assessed based on data recorded up to 28 days and up to 6 months after randomisation.

Where available, data from routine healthcare records (including linkage to medical databases held by organisations such as NHS Digital in the UK) and from relevant research studies (such as UK Biobank, Genomics England, ISARIC-4C and PHOSP-COVID) will allow subsidiary analyses of the effect of the study treatments on particular non-fatal events (e.g. ascertained through linkage to Hospital Episode Statistics), the influence of pre-existing major co-morbidity (e.g. diabetes, heart disease, lung disease, hepatic insufficiency, severe depression, severe kidney impairment, immunosuppression), and longer-term outcomes as well as in particular sub-categories of patient (e.g. by genotype, pregnancy).

3.2 Methods of analysis

For all outcomes, comparisons will be made between all participants randomised to the different treatment arms, irrespective of whether they received their allocated treatment ("intention-to-treat" analyses).

For time-to-event analyses, each treatment group will be compared with the no additional treatment group using the log-rank test. Kaplan-Meier estimates for the time to event will also be plotted (with associated log-rank p-values). The log-rank ‘observed minus expected’ statistic (and its variance) will also be used to estimate the average event rate ratio (and its
confidence interval) for those allocated to each treatment group versus the no additional treatment group. For binary outcomes where the timing is unknown, the risk ratio and absolute risk difference will be calculated with confidence intervals and p-value reported. For the primary outcome (death within 28 days of randomisation), discharge alive before 28 days will assume safety from the event (unless there is additional data confirming otherwise).

Pairwise comparisons within each randomisation will be made between each treatment arm and the no additional treatment arm (reference group) in that particular randomisation (main randomisation part A, B, C, D, E or F and second randomisation). However, since not all treatments may be available or suitable for all patients, those in the no additional treatment arm will only be included in a given comparison if, at the point of their randomisation, they could alternatively have been randomised to the active treatment of interest. Allowance for multiple treatment comparisons due to the multi-arm design will be made. All p-values will be 2-sided.

Pre-specified subgroup analysis (e.g., level of respiratory support, time since onset of symptoms; sex; age group; ethnicity; use of corticosteroids) will be conducted for the primary outcome using the statistical test for interaction (or test for trend where appropriate). Sensitivity analyses will be conducted among those patients with laboratory confirmed SARS-CoV-2. Further details will be fully described in the Statistical Analysis Plan.

3.3 Children
The primary outcome for children will be the number of days in hospital. This will be analysed using a negative binomial model utilizing a Bayesian framework with treatment indicators for tocilizumab and anakinra as well as site and age. Non-informative prior distributions will be used for the treatment effects and mildly informative priors for the covariates. Further details will be described in a children-specific statistical analysis plan which will be agreed prior to unblinding any results to the Steering Committee.

3.4 Early phase assessments
The primary objective for the early phase assessment of dimethyl fumarate is to assess the effect of dimethyl fumarate on the S/F94 ratio. The primary comparison will involve an “intention to treat” analysis among all participants randomised between dimethyl fumarate and its control and its control of the effect of dimethyl fumarate on SpO2:FiO2 ratio at day 5. Secondary objectives include assessment of the effect of dimethyl fumarate on: time to improvement by at least one category from the WHO ordinal scale at baseline; time to discharge; odds of improvement in clinical status at day 10; average WHO ordinal scale on days 3, 7 and 10; and study average blood C-reactive protein. These data (along with information on tolerability and safety) would be reviewed to determine whether the balance of information favours assessing dimethyl fumarate in a larger comparison or not. Full details will be described in a statistical analysis plan which will be agreed prior to unblinding any results to the Steering Committee.

Based on unpublished data from 8500 patients with COVID-19, assuming a mean (standard deviation) S/F94 ratio of 3.3 (1.7) at day 5, and a correlation between an individual’s baseline and day 5 S/F94 ratio of 0.5, randomisation of 400 participants will provide 90% power (at 2p=0.05) to detect a difference in S/F94 ratio of 0.5 (the chosen minimum clinically
meaningful difference [which is similar to the difference in 1 point on the WHO ordinal scale]),
even if 10% of participants discontinue study treatment before day 5.

4 DATA AND SAFETY MONITORING

4.1 Recording Suspected Serious Adverse Reactions
The focus is on those events that, based on a single case, are highly likely to be related to
the study medication. Examples include anaphylaxis, Stevens Johnson Syndrome, or bone
marrow failure, where there is no other plausible explanation.

Any Serious Adverse Event that is believed with a reasonable probability to be due to one
of the study treatments will be considered a Suspected Serious Adverse Reaction (SSAR). In
making this assessment, there should be consideration of the probability of an alternative
cause (for example, COVID-19 itself or some other condition preceding randomisation), the
timing of the event with respect to study treatment, the response to withdrawal of the study
treatment, and (where appropriate) the response to subsequent re-challenge.

All SSARs should be reported by telephone to the Central Coordinating Office and recorded
on the study IT system immediately.

4.2 Central assessment and onward reporting of SUSARs

Clinicians at the Central Coordinating Office are responsible for expedited review of reports
of SSARs received. Additional information (including the reason for considering it both
serious and related, and relevant medical and medication history) will be sought.

The focus of Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting will be
on those events that, based on a single case, are highly likely to be related to the study
medication. To this end, anticipated events that are either efficacy endpoints, consequences
of the underlying disease, or common in the study population will be exempted from
expedited reporting. Thus the following events will be exempted from expedited reporting:

(i) Events which are the consequence of COVID-19; and
(ii) Common events which are the consequence of conditions preceding randomisation.

Any SSARs that are not exempt will be reviewed by a Central Coordinating Office clinician
and an assessment made of whether the event is “expected” or not (assessed against the
relevant Summary of Product Characteristics or Investigator Brochure). Any SSARs that are
not expected would be considered a Suspected Unexpected Serious Adverse Reaction (SUSAR).

---

1 Serious Adverse Events are defined as those adverse events that result in death; are life-threatening; require in-patient
hospitalisation or prolongation of existing hospitalisation; result in persistent or significant disability or incapacity; result in
congenital anomaly or birth defect; or are important medical events in the opinion of the responsible investigator (that is, not
life-threatening or resulting in hospitalisation, but may jeopardise the participant or require intervention to prevent one
or other of the outcomes listed above).
All confirmed SUSARs will be reported to the Chair of the DMC and to relevant regulatory authorities, ethics committees, and investigators in an expedited manner in accordance with regulatory requirements.

4.3 Recording other Adverse Events
In addition to recording Suspected Serious Adverse Reactions (see section 4.1), information will be collected on all deaths and efforts will be made to ascertain the underlying cause. Other serious or non-serious adverse events will not be recorded unless specified in section 2.7. It is anticipated that for some substudies, more detailed information on adverse events (e.g. through linkage to medical databases) or on other effects of the treatment (e.g. laboratory or radiological features) will be recorded and analysed but this is not a requirement of the core protocol.

4.4 Role of the Data Monitoring Committee (DMC)
During the study, interim analyses of all study data will be supplied in strict confidence to the independent DMC. The DMC will request such analyses at a frequency relevant to the emerging data from this and other studies.

The DMC will independently evaluate these analyses and any other information considered relevant. The DMC will determine if, in their view, the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. Unless this happens, the Trial Steering Committee, Chief Investigator, study staff, investigators, study participants, funders and other partners will remain blind to the interim results until 28 days after the last patient has been randomised for a particular intervention arm (at which point analyses may be conducted comparing that arm with the no additional treatment arm).

The DMC will review the safety and efficacy analyses among children (age <18 years) both separately and combined with the adult data.

4.5 Blinding
This is an open-label study. However, while the study is in progress, access to tabular results of study outcomes by allocated treatment allocation will not be available to the research team, patients, or members of the Trial Steering Committee (unless the DMC advises otherwise).

* Outside the UK, additional serious adverse event information (event description, date of onset, outcome, relatedness to study treatment) will be collected if required by national regulations. This will be collected on a web-based case report form and any forms required by local regulations.
5 QUALITY MANAGEMENT

5.1 Quality By Design Principles
In accordance with the principles of Good Clinical Practice and the recommendations and guidelines issued by regulatory agencies, the design, conduct and analysis of this trial is focussed on issues that might have a material impact on the wellbeing and safety of study participants (hospitalised patients with suspected or confirmed SARS-CoV-2 infection) and the reliability of the results that would inform the care for future patients.

The critical factors that influence the ability to deliver these quality objectives are:

- to minimise the burden on busy clinicians working in an overstretched hospital during a major epidemic
- to ensure that suitable patients have access to the trial medication without impacting or delaying other aspects of their emergency care
- to provide information on the study to patients and clinicians in a timely and readily digestible fashion but without impacting adversely on other aspects of the trial or the patient’s care
- to allow individual clinicians to use their judgement about whether any of the treatment arms are not suitable for the patient
- to collect comprehensive information on the mortality and disease status

In assessing any risks to patient safety and well-being, a key principle is that of proportionality. Risks associated with participation in the trial must be considered in the context of usual care. At present, there are no proven treatments for COVID-19, basic hospital care (staffing, beds, ventilatory support) may well be overstretched, and mortality for hospitalised patients may be around 10% (or more in those who are older or have significant co-morbidity).

5.2 Training and monitoring
The focus will be on those factors that are critical to quality (i.e. the safety of the participants and the reliability of the trial results). Remedial actions would focus on issues with the potential to have a substantial impact on the safety of the study participants or the reliability of the results.

The study will be conducted in accordance with the principles of International Conference on Harmonisation Guidelines for Good Clinical Research Practice (ICH-GCP) and relevant local, national and international regulations. Any serious breach of GCP in the conduct of the clinical trial will be handled in accordance with regulatory requirements. Prior to initiation of the study at each Local Clinical Centre (LCC), the Central Coordinating Office (CCO) or relevant Regional Coordinating Centre (RCC) will confirm that the LCC has adequate facilities and resources to carry out the study. LCC lead investigators and study staff will be provided with training materials.

In the context of this epidemic, visits to hospital sites is generally not appropriate as they could increase the risks of spreading infection, and in the context of this trial they generally would not influence the reliability of the trial results or the well-being of the participants. In exceptional circumstances, the CCO or RCC may arrange monitoring visits to LCCs as considered appropriate based on perceived training needs and the results of central...
statistical monitoring of study data.\textsuperscript{11,12} The purpose of such visits will be to ensure that the study is being conducted in accordance with the protocol, to help LCC staff to resolve any local problems, and to provide extra training focussed on specific needs. No routine source data verification will take place.

5.3 Data management
LCC clinic staff will use the bespoke study web-based applications for study management and to record participant data (including case report forms) in accordance with the protocol. Data will be held in central databases located at the CCO or on secure cloud servers. In some circumstances (e.g. where there is difficulty accessing the internet or necessary IT equipment), paper case report forms may be required with subsequent data entry by either LCC or CCO staff. Although data entry should be mindful of the desire to maintain integrity and audit trails, in the circumstances of this epidemic, the priority is on the timely entry of data that is sufficient to support reliable analysis and interpretation about treatment effects. CCO staff will be responsible for provision of the relevant web-based applications and for generation of data extracts for analyses.

All data access will be controlled by usernames and passwords, and any changes to data will require the user to enter their username and password. Staff will have access restricted to the functionality and data that are appropriate for their role in the study.

5.4 Source documents and archiving
Source documents for the study constitute the records held in the study main database. These will be retained for at least 25 years from the completion of the study. Identifiable data will be retained only for so long as it is required to maintain linkage with routine data sources (see section 2.8), with the exception of children for whom such data must be stored until they reach 21 years old (due to the statute of limitations). The sponsor and regulatory agencies will have the right to conduct confidential audits of such records in the CCO and LCCs (but should mindful of the workload facing participating hospitals and the infection control requirements during this epidemic).

6 OPERATIONAL AND ADMINISTRATIVE DETAILS

6.1 Sponsor and coordination
The University of Oxford will act as the trial Sponsor. The trial will be coordinated by a Central Coordinating Office (CCO) within the Nuffield Department of Population Health staffed by members of the two registered clinical trials units – the Clinical Trial Service Unit and the National Perinatal Epidemiology Unit Clinical Trials Unit. The CCO will oversee Regional Coordinating Centres which will assist with selection of Local Clinical Centres (LCCs) within their region and for the administrative support and monitoring of those LCCs. The data will be collected, analysed and published independently of the source of funding.

6.2 Funding
This study is supported by grants to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and the Wellcome Trust, and by core funding provided by NIHR Oxford Biomedical Research Centre, the Wellcome Trust,
the Bill and Melinda Gates Foundation, Department for International Development, Health Data Research UK, NIHR Health Protection Unit in Emerging and Zoonotic Infections and the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.

6.3 Indemnity
The University has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting Management Ltd, at Lloyd’s of London). In the UK, NHS indemnity operates in respect of the clinical treatment that is provided.

6.4 Local Clinical Centres
The study will be conducted at multiple hospitals (LCCs) within each region. At each LCC, a lead investigator will be responsible for trial activities but much of the work will be carried out by medical staff attending patients with COVID-19 within the hospital and by hospital research nurses, medical students and other staff with appropriate education, training, and experience. Where LCCs plan to recruit children the principal investigator will co-opt support from a local paediatrician and/or neonatologists to oversee the management of children and infants in the trial.

6.5 Supply of study treatments
For licensed treatments (e.g. corticosteroids, baricitinib) all aspects of treatment supply, storage, and management will be in accordance with standard local policy and practice for prescription medications. Treatments issued to randomised participants will be by prescription. Such study treatments will not be labelled other than as required for routine clinical use. They will be stored alongside other routine medications with no additional monitoring. No accountability records will be kept beyond those used for routine prescriptions.

For unlicensed treatments, manufacture, packaging, labelling and delivery will be the responsibility of the pharmaceutical company and, in the UK, the Department of Health and Social Care. Each LCC will maintain an accountability log and will be responsible for the storage and issue of study treatment. If treatments require storage at a specific temperature, LCCs can use existing temperature-controlled facilities and associated monitoring. Treatment issue to randomised participants will be in accordance with local practice (and may be in line with the processes required for routine prescriptions or compassionate use).

Treatment will be issued to randomised participants by prescription.

6.6 End of trial
The end of the scheduled treatment phase is defined as the date of the last follow-up visit of the last participant. In the UK, it is intended to extend follow-up for a year or more beyond the final study visit through linkage to routine medical records and central medical databases. The end of the study is the date of the final data extraction from NHS Digital (anticipated to be 10 years after the last patient is enrolled).

6.7 Publications and reports
The Trial Steering Committee will be responsible for drafting the main reports from the study and for review of any other reports. In general, papers initiated by the Trial Steering
Committee (including the primary manuscript) will be written in the name of the RECOVERY Collaborative Group, with individual investigators named personally at the end of the report (or, to comply with journal requirements, in web-based material posted with the report).

The Trial Steering Committee will also establish a process by which proposals for additional publications (including from independent external researchers) are considered by the Trial Steering Committee. The Trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Trial Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Trial Steering Committee will have the right to review and comment on any draft manuscripts prior to publication.

6.8 Substudies
Proposals for substudies must be approved by the Trial Steering Committee and by the relevant ethics committee and competent authorities (where required) as a substantial amendment or separate study before they begin. In considering such proposals, the Trial Steering Committee will need to be satisfied that the proposed substudy is worthwhile and will not compromise the main study in any way (e.g. by impairing recruitment or the ability of the participating hospitals to provide care to all patients under their care).
## 7 VERSION HISTORY

<table>
<thead>
<tr>
<th>Version number</th>
<th>Date</th>
<th>Brief Description of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>13-Mar-2020</td>
<td>Initial version</td>
</tr>
<tr>
<td>2.0</td>
<td>21-Mar-2020</td>
<td>Addition of hydroxychloroquine. Administrative changes and other clarifications.</td>
</tr>
<tr>
<td>4.0</td>
<td>14-Apr-2020</td>
<td>Addition of second randomisation to tocilizumab vs. standard of care among patients with progressive COVID-19.</td>
</tr>
<tr>
<td>5.0</td>
<td>24-Apr-2020</td>
<td>Addition of children to study population.</td>
</tr>
<tr>
<td>6.0</td>
<td>14-May-2020</td>
<td>Addition of convalescent plasma</td>
</tr>
<tr>
<td>7.0</td>
<td>18-Jun-2020</td>
<td>Allowance of randomisation in part B of main randomisation without part A. Removal of hydroxychloroquine and dexamethasone treatment arms.</td>
</tr>
<tr>
<td>9.0</td>
<td>10-Sep-2020</td>
<td>Addition of synthetic neutralizing antibodies. Additional baseline data collection. Addition of countries outside UK.</td>
</tr>
<tr>
<td>9.1</td>
<td>18-Sep-2020</td>
<td>Addition of information about vaccination of children of pregnant mothers receiving REGN10933+REGN10987.</td>
</tr>
<tr>
<td>10.0</td>
<td>26-Oct-2020</td>
<td>Addition of main randomisation part C. General updates to avoid duplication and improve clarity.</td>
</tr>
<tr>
<td>10.1</td>
<td>01-Nov-2020</td>
<td>Additional information for pregnant women.</td>
</tr>
<tr>
<td>11.0</td>
<td>19-Nov-2020</td>
<td>Addition of colchicine to main randomisation part A. Removal of azithromycin from main randomisation part A. Change in randomisation ratio in main randomisation part A from 2:1 to 1:1.</td>
</tr>
<tr>
<td>11.1</td>
<td>21-Nov-2020</td>
<td>Clarification of colchicine age thresholds.</td>
</tr>
<tr>
<td>11.2 [not submitted in UK]</td>
<td>01-Dec-2020</td>
<td>Addition of modified aspirin dose if 150mg not available.</td>
</tr>
<tr>
<td>12.0</td>
<td>10-Dec-2020</td>
<td>Allow second randomisation of children without first randomisation.</td>
</tr>
<tr>
<td>12.1</td>
<td>16-Dec-2020</td>
<td>Clarification of change in V12.0.</td>
</tr>
<tr>
<td>13.0</td>
<td>26-Jan-2021</td>
<td>Addition of baricitinib and anakinra (and change to allocation ratio in second randomization for children); addition of pregnancy test for women of child-bearing potential (and change to colchicine eligibility); removal of tocilizumab for adults; removal of convalescent plasma and additional assessment of antibody-based therapy; addition of dexamethasone as substitute if methylprednisolone unavailable</td>
</tr>
<tr>
<td>14.0</td>
<td>15-Feb-2021</td>
<td>Addition of Early Phase Assessments; the inclusion of dimethyl fumarate for initial early phase assessment; restriction of main randomisation part B to children with COVID-19 pneumonia; modification of baricitinib and tocilizumab co-administration guidance</td>
</tr>
<tr>
<td>15.0</td>
<td>12-Apr-2021</td>
<td>Removal of aspirin and colchicine; addition of infliximab and high-dose corticosteroids (ex-UK only)</td>
</tr>
<tr>
<td>15.1 [not submitted in UK]</td>
<td>18-May-2021</td>
<td>Addition of South Africa</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td><strong>16.0</strong></td>
<td>05-Jul-2021</td>
<td>Removal of REGN-COV2 and main randomisation part B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Removal of infliximab from main randomisation part E (and associated endemic infection monitoring section)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Addition of empagliflozin as main randomisation part F and metabolic outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Addition of India, Sri Lanka and Pakistan</td>
</tr>
</tbody>
</table>
8 APPENDICES

8.1 Appendix 1: Information about the treatment arms

All patients will receive usual care in the participating hospital.

Corticosteroids: RECOVERY is assessing corticosteroids in the following contexts:
  i. Moderate dose vs usual care in neonates with COVID-19 pneumonia (UK only)
  ii. High dose vs usual care in children with PIMS-TS (UK only)
  iii. High dose vs usual care in adults with COVID-19 and hypoxia (ex-UK only)

Favourable modulation of the immune response is considered one of the possible mechanisms by which corticosteroids might be beneficial in the treatment of severe acute respiratory coronavirus infections, including COVID-19, SARS and MERS. Common to severe cases of these infections is the presence of hypercytokinemia and the development of acute lung injury or acute respiratory distress syndrome (ARDS). Pathologically, diffuse alveolar damage is found in patients who die from these infections. RECOVERY and other randomised trials have now demonstrated the benefit of corticosteroids in hypoxic COVID-19 patients.

RECOVERY showed that a dose of 6mg dexamethasone once daily for ten days or until discharge (which ever happens earliest) provided a significant reduction in mortality. Combining the IL-6 inhibitor tocilizumab with low dose dexamethasone resulted in a further reduction in mortality. This raises the question whether simply increasing the dose of corticosteroid could confer a similar clinical benefit to that of adding tocilizumab, but at substantially lower cost. Of note, even with dexamethasone 6mg and tocilizumab, mortality remained high at 29%. Although other randomised clinical trials in critically ill COVID-19 patients have used higher doses of dexamethasone (20mg once daily for five days followed by 10mg once daily for a further five days) and reported clinical benefit, these doses have not been compared with the lower dose used in RECOVERY. There is, therefore, uncertainty regarding the optimal dose of corticosteroids in moderate to severe COVID-19. Uncertainty remains about whether higher doses of corticosteroids may provide additional benefit in adults with hypoxia hospitalised with COVID-19.

Unlike lower doses, higher doses (>15mg dexamethasone) would completely saturate cytosolic glucocorticoid receptors and have enhanced non-genomic effects. In conditions where rapid control of inflammatory processes are required, short-term, high to very high doses of corticosteroids are used e.g.

- Sepsis 7.5 - 15mg dexamethasone equivalent daily
- ARDS: 20mg dexamethasone for five days followed by 10mg for five days
- Bacterial meningitis: 40mg dexamethasone daily for four days
- Tuberculous Meningitis 0.4mg/k/day dexamethasone for 7 days then reducing over 8 weeks
- Rheumatoid arthritis flare: 120mg dexamethasone pulse therapy
- Community acquired pneumonia: 0.6mg/day dexamethasone for 2 days and methyl prednisolone 200m g /day then 80m g /day for 10 days.
PIMS-TS is associated with a hyper-inflammatory state with elevated ESR, C-reactive protein, D-dimers, lactate dehydrogenase, ferritin, and increased levels of pro-inflammatory cytokines including as IL-1 and IL-6. While there is a pharmacological basis for using high dose methylprednisolone, the Delphi consensus process conducted by NHS England identified equipoise for its use in the treatment of PIMS-TS.

[UK only] Dimethyl fumarate: Dimethyl fumarate (DMF) is thought to prevent NLRP3 inflammasome activation and the process of pyroptosis (inflammatory cell death) through its action on the protein gasdermin D.\(^27\) SARS-CoV-2 induces inflammasome activation and the degree of activation is thought to correlate with disease severity.\(^28\) DMF has demonstrated anti-viral and anti-inflammatory effects against SARS-CoV-2 \textit{in vitro}.\(^29\) Other inflammasome-modulating drugs, such as colchicine, have demonstrated provisionally promising results in small randomised trials.\(^30,31\) DMF is licensed to treat relapsing remitting multiple sclerosis and plaque psoriasis as a long-term immunomodulatory agent and is generally well-tolerated with no major safety concerns.\(^32,33\) The UK COVID-19 Therapeutics Advisory Panel has recommended that RECOVERY investigate the safety and efficacy of DMF in an early phase assessment among patients hospitalised with COVID-19.

[UK only] Baricitinib: Baricitinib is a JAK (Janus kinase) 1/2 inhibitor licensed for the treatment of rheumatoid arthritis and atopic dermatitis. JAK 1/2 inhibition prevents downstream phosphorylation (and hence activation) of STAT (signal transducers and activators of transcription). The JAK-STAT pathway mediates the effect of several interleukins (including IL-6), so JAK inhibitors reduce the cascade of inflammatory mediators that derive from IL-6 activation of its receptor. Baricitinib also binds tyrosine kinase 2, preventing its activation.\(^34\) Recent genetic data support a causal link between high tyrosine kinase expression (hence activity) and severe COVID-19.\(^35\) Baricitinib was tested in the Adaptive Covid-19 Treatment Trial-2 and was shown to improve time to recovery (rate ratio for recovery 1.16, 95% CI 1.01-1.32). 28-day mortality was 5.1% among participants allocated baricitinib compared to 7.8% allocated placebo (HR 0.65, 95% CI 0.39-1.09).\(^36\) Serious adverse events were less frequent among participants allocated baricitinib (16.0% vs. 21.0%; p=0.03).

[UK only] Intravenous immunoglobulin (IVIg): IVIg is human normal immunoglobulin, available in a number of different preparations in routine NHS practice. The NHS England consensus process has established intravenous immunoglobulin as the interim first line treatment in non-shocked COVID-associated PIMS-TS and also that there is need for evaluation of intravenous immunoglobulin and corticosteroid in the initial management of PIMS-TS. In the similar but different disease process known as Kawasaki Diseases, randomised controlled trials and meta-analyses have demonstrated that early recognition and treatment of KD with IVIg (and aspirin) reduces the occurrence of coronary artery aneurysms. Current published guidelines recommend a dose of 2 g/kg IVIg given as a single infusion, as this has been shown to reduce the coronary artery aneurysm rate compared to a lower divided dose regimen.\(^37\) IVIg is licensed for immunomodulation in adults, children and adolescents (0-18 years) in a number of clinical conditions including but not limited to primary immune thrombocytopenia, Guillain Barré syndrome, Kawasaki disease (in association with aspirin), chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy.
[UK only] Tocilizumab is a monoclonal antibody that binds to the receptor for IL-6, blocking IL-6 signalling and reduces inflammation. Tocilizumab is licensed for use in patients with rheumatoid arthritis and for use in people aged at least 2 years with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.

Severe COVID-19 is associated with a hyper-inflammatory state with elevated ESR, C-reactive protein, D-dimers, lactate dehydrogenase, ferritin, and increased levels of pro-inflammatory cytokines including as IL-1 and IL-6. There have been published and unpublished (pre-print) case series reports of the successful treatment of COVID-19 patients with IL-6 inhibitors. IL-6 inhibitors have not been evaluated for the treatment of COVID-19 in randomised controlled trials.

[UK only] Anakinra: Anakinra is an antagonist of the interleukin-1 receptor licensed for the treatment of rheumatoid arthritis, periodic fever syndromes and Still's disease. Anakinra is widely used in several paediatric conditions with hyperinflammation including macrophage activation syndrome, systemic JIA and autoinflammatory disorders. The hyperinflammatory syndrome associated with COVID-19 in children (PIMS-TS) is characterised by high inflammatory markers and wide range of elevated cytokines. Immunomodulatory therapy with IL-1 inhibition using anakinra has been used in the management of the children with PIMS-TS, but controlled trials are lacking. Anakinra has been shown to be safe in sepsis and has a short half-life which may be advantageous for use in very ill children with PIMS-TS.

Empagliflozin: Sodium glucose co-transporter 2 inhibitors (SGLT-2i) decrease glucose and insulin levels, and shift energy metabolism to an increased reliance on lipid oxidation, with a reduced reliance on glucose, and inhibition of glycolysis. This mechanism may be particularly important in COVID-19, as SARS-CoV-2 may depend on the glycolytic pathway for its replication, stimulating lipogenesis, which appears to be one of the key drivers of cellular damage. SGLT-2i rapidly improve endothelial function, possibly because of reduced oxidative stress. SGLT-2i have significant anti-inflammatory effects, reducing levels of C-reactive protein and interleukin-6. Experimental studies have also shown reduced activation of the NLRP3 inflammasome. SGLT-2i increase erythropoiesis resulting in increased haematocrit, and together with improved endothelial function may improve oxygen delivery to tissues. Moreover, SGLT-2i result in reduced extracellular volume in patients with fluid overload, and appear to reduce pulmonary artery pressure in patients with heart failure rapidly, leading to haemodynamic decongestion. Thus, SGLT-2i may favourably affect multiple processes, including but not limited to energy metabolism, endothelial function, oxidative stress, inflammation and autophagy, which are dysregulated during a major acute illness such as COVID-19. The DARE-19 trial compared dapagliflozin 10 mg with placebo for 30 days among 1250 patients admitted to hospital with COVID-19 who had mild hypoxia (SpO2 ≥94% on ≤5 L/min oxygen) and at least one risk factor (hypertension, type 2 diabetes mellitus, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease). The treatment was well tolerated (11% discontinued prematurely with similar proportion in treatment and placebo group). The hazard ratio for the co-primary outcome of organ failure (non-invasive or invasive ventilation, requirement for cardiovascular support or new/worsened heart failure, doubling of creatinine or dialysis) or death was 0.80 (95% CI 0.58-1.10; 70 vs 86 events). Although this trial lacked statistical sensitivity, it supports the rationale for a larger trial.
8.2 Appendix 2: Drug specific contraindications and cautions

Corticosteroid
Contraindications:
- Known contra-indication to short-term corticosteroid.
Endemic infections may be screened for as required by local practice.

Dimethyl fumarate
Contraindications:
- Pregnancy
- Breast-feeding
- Known hypersensitivity to excipients in any oral therapy

If symptoms develop which the participant or their doctor attributes to dimethyl fumarate (e.g. flushing, gastrointestinal disturbance), its dose may be reduced e.g. from 240 mg twice daily to 120 mg twice daily or 120 mg once daily (or it may be discontinued if considered necessary by the managing clinician or participant).

Baricitinib
Contraindications:
- eGFR <15 mL/min/1.73m² (including participants on dialysis/haemofiltration)
- Neutrophil count <0.5 x 10⁹/L
- Evidence of active TB infection
- Pregnancy

Cautions:
- Dose should be reduced in presence of renal impairment
  - eGFR ≥30 <60 mL/min/1.73m²: 2 mg once daily
  - eGFR ≥15 <30 mL/min/1.73m²: 2 mg on alternate days
- Dose should be halved in patients also taking probenecid
- Baricitinib and tocilizumab may be co-administered, but the managing clinician should consider the risk of infection and gastrointestinal perforation (which may present atypically due to suppressed C-reactive protein production and concomitant corticosteroids)

Intravenous Immunoglobulin (children only)
- Hypersensitivity to the active substance (human immunoglobulins) or to any of the excipients
- Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA-containing product can result in anaphylaxis
- Hyperprolinaemia type I or II.

Potential complications can often be avoided by ensuring that participants:
  i. are carefully monitored for any symptoms throughout the infusion period;
  ii. have urine output and serum creatinine levels monitored; and
  iii. avoid concomitant use of loop diuretics.
Such monitoring should occur regularly during the admission, at a frequency appropriate to the illness of the child.
**Tocilizumab**
- Known hypersensitivity to tocilizumab.
- Evidence of active TB infection\(^1\)
- Clear evidence of active bacterial, fungal, viral, or other infection (besides COVID-19)
  (Note: Pregnancy and breastfeeding are not exclusion criteria.)

**Anakinra**
- Known hypersensitivity to anakinra
- Neutrophil count \(<1.5 \times 10^9\) cells/L
- Pregnancy

**Empagliflozin**

Contraindications:
- Type 1 diabetes mellitus
- Pregnancy and breast-feeding

Cautions:
- Clinicians should consider temporarily discontinuing empagliflozin in participants with type 2 diabetes mellitus who cannot maintain oral calorific intake (until nutrition is restored)
- Clinicians should be aware of “euglycaemic ketoacidosis” which occurs with empagliflozin and should check ketones (ideally blood) if this is suspected (e.g. unexplained metabolic acidosis)
- Empagliflozin does not cause hypoglycaemia alone, but may do so in combination with insulin or insulin secretagogues (e.g. sulphonylureas). Doses of these other medications may need to be temporarily modified while the participant is taking empagliflozin
- Empagliflozin causes an osmotic diuresis so careful fluid balance assessment is required
- Empagliflozin increases the risk of mycotic genital infections (e.g. candidiasis) which are usually easily treated with topical therapy. It is unclear whether it causes Fournier’s gangrene (a very rare genital infection), but clinicians should be aware.

---

\(^1\) Note: The risk of reactivation of latent tuberculosis with tocilizumab is considered to be extremely small.
8.3 Appendix 3: Paediatric dosing information

Children (aged <18 years old) will be recruited in the UK only.

### Main Randomisation Part A

<table>
<thead>
<tr>
<th>Arm</th>
<th>Route</th>
<th>Weight/Age #</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>No additional treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Corticosteroid</strong></td>
<td>Intravenous</td>
<td>Neonates/infants with a corrected gestational age of ≤44 weeks with COVID-19 pneumonia</td>
<td><strong>Hydrocortisone</strong> (IV): 0.5 mg/kg every 12 hours for 7 days and then 0.5mg/kg once daily for 3 days</td>
</tr>
<tr>
<td>- Solution for injection*</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Powder for solution for injection*</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- *various strengths available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human normal immunoglobulin (IVIg)</strong></td>
<td>Intravenous</td>
<td>&gt;44 weeks with PIMS-TS</td>
<td><strong>Methylprednisolone sodium succinate</strong>† 10 mg/kg (as base) once daily for 3 days (max 1 gram) No additional oral corticosteroid should be prescribed to follow the 3 day treatment course.</td>
</tr>
<tr>
<td>- solution for infusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- *various strengths available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Baricitinib</strong></td>
<td>Oral/ other enteral routes</td>
<td>≥ 2 years with COVID-19 pneumonia</td>
<td>Once daily for 10 days or until discharge, whichever is sooner</td>
</tr>
<tr>
<td>- 2 and 4 mg tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Weight to be rounded to the nearest kg unless dosage expressed as mg/kg or mL/kg.
† If methylprednisolone is unavailable, intravenous dexamethasone may be substituted (0.3 mg/kg as base; max 19.8 mg) once daily for 3 days.
## Second stage randomisation (Patients < 1 year of age will **NOT** be eligible)

<table>
<thead>
<tr>
<th>Arm</th>
<th>Route</th>
<th>Weight</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>No additional treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Tocilizumab</strong></td>
<td>Intravenous</td>
<td>Infants &lt; 1 year excluded</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 30 kg</td>
<td>12 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(\geq 30) kg</td>
<td>8 mg/kg (max 800 mg)</td>
</tr>
<tr>
<td><strong>Anakinra</strong></td>
<td>Subcutaneous (Intravenous route if clinically required)</td>
<td>Infants &lt; 1 year or &lt;10 kg excluded</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(\geq 10) kg</td>
<td>2 mg/kg daily for 7 days or discharge whichever is sooner</td>
</tr>
</tbody>
</table>
8.4 Appendix 4: Use of IMPs in pregnant and breastfeeding women

All trial drugs (except baricitinib and empagliflozin) have been used in pregnant women with pre-existing medical disorders where benefits outweigh the risks to fetus or woman, including in the first trimester. The existing data related to each drug is summarized below.

**Dimethyl fumarate**

Dimethyl fumarate is contraindicated in pregnant or breastfeeding women. Dimethyl fumarate will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

**Corticosteroids**

Prednisolone or, in women unable to take oral medicine, hydrocortisone or methylprednisolone are recommended instead of dexamethasone treatment in light of accumulating evidence that repeated doses of dexamethasone have deleterious effects on long-term neurodevelopment of the fetus. While 90% dexamethasone is transferred transplacentally to the fetus, both hydrocortisone and prednisolone are converted by 11β-hydroxysteroid dehydrogenase to inactive glucocorticoids and considerbly less drug is transferred to the fetus. Glucocorticoids can worsen maternal glycaemic control, so blood glucose should be checked and managed appropriately. Otherwise there is no convincing evidence that prednisolone use is associated with increased rates of adverse pregnancy outcomes when taken in the first trimester or later pregnancy. Very low concentrations of prednisolone enter breastmilk. There is a paucity of data about pharmacological use of hydrocortisone, but it is likely that this is also safe when breastfeeding, as also reviewed in the Lactmed database (www.ncbi.nlm.nih.gov/books/NBK501076/). Prednisolone (or hydrocortisone) should be used in breastfeeding women, in preference to dexamethasone.

**Tocilizumab**

Two pharmaceutical global safety registry database studies have reported on tocilizumab use in pregnancy, including outcomes from 288 pregnancies and 61 pregnancies, typically for rheumatoid or other arthritides, and with the majority having received the drug in the first trimester. These data suggest that the rates of congenital abnormality, spontaneous pregnancy loss and other adverse outcomes were not higher than in the general population. Small studies have shown that tocilizumab is transferred to the fetus with serum concentrations approximately 7-fold lower than those observed in maternal serum at the time of birth. Very low concentrations of tocilizumab are identified in breast milk and no drug is transferred into the serum of breast fed infants. Women should be advised that if treated after 20 weeks’ gestation, their infant should not be immunised with live vaccines (rotavirus and BCG) for the first 6 months of life. All non-live vaccinations are safe and should be undertaken.

**Baricitinib**

Baricitinib is contraindicated in pregnant or breastfeeding women. Baricitinib will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

**Anakinra**

Data on the use of anakinra in pregnancy data are currently limited. Although renal agenesis and oligohydramnios have been described in exposed infants, controlled studies are lacking.
Anakinra will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

**Empagliflozin**
Empagliflozin is not recommended for use in pregnant or breastfeeding women.
8.5 Appendix 5: Early phase assessment details

S/F\textsubscript{94} ratio:
The Sp\textsubscript{O}_2:FiO\textsubscript{2} ratio is a simple correction for the measured oxygen saturation (Sp\textsubscript{O}_2) to account for how much oxygen the patient is receiving (FiO\textsubscript{2}). If the measured Sp\textsubscript{O}_2 is >94% the ratio is less accurate (because it cannot rise much further regardless of FiO\textsubscript{2}). Therefore the Sp\textsubscript{O}_2:FiO\textsubscript{2} ratio will be measured when the patient’s Sp\textsubscript{O}_2 is <94% (called the S/F\textsubscript{94}).

The participant should be resting in bed with the head of the bed at 30\degree for at least 10 minutes. If they are receiving oxygen via simple nasal prongs or face mask, this will be switched to a Venturi mask (which controls FiO\textsubscript{2} more precisely). The FiO\textsubscript{2} will then be reduced gradually until Sp\textsubscript{O}_2 <94% (or the participant is receiving room air, i.e. FiO\textsubscript{2} = 0.21).

Short periods of hypoxia (e.g. Sp\textsubscript{O}_2 of 80%) are not considered harmful. The participant should be monitored throughout and if they become breathless or distressed after a reduction in FiO\textsubscript{2} it will be immediately increased. Once Sp\textsubscript{O}_2 <94% (or the participant is breathing room air) the details of oxygen delivery mode, Sp\textsubscript{O}_2, FiO\textsubscript{2} and respiratory rate will be recorded. The participant’s oxygen will then be returned to baseline. Further details will be provided in a Standard Operating Procedure.

WHO Ordinal Scale
The World Health Organization have endorsed the use of an ordinal scale as an outcome measure in clinical trials in order to capture the trajectory of patients’ clinical progression and of healthcare resource use.\textsuperscript{10}

<table>
<thead>
<tr>
<th>Score</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Discharged (alive)</td>
</tr>
<tr>
<td>2</td>
<td>Hospital admission, not requiring supplemental oxygen, no longer requiring medical care (hospitalisation extended for infection control or other nonmedical reasons e.g. social care. Sometimes documented as “medically fit for discharge” or “medically stable for discharge”)</td>
</tr>
<tr>
<td>3</td>
<td>Hospital admission, not requiring supplemental oxygen, but requiring ongoing medical care</td>
</tr>
<tr>
<td>4</td>
<td>Hospital admission, requiring supplemental oxygen (by face mask or nasal prongs)</td>
</tr>
<tr>
<td>5</td>
<td>Hospital admission, requiring high flow nasal oxygen, continuous positive airways pressure or non-invasive ventilation</td>
</tr>
<tr>
<td>6</td>
<td>Hospital admission, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)</td>
</tr>
<tr>
<td>7</td>
<td>Death</td>
</tr>
</tbody>
</table>
8.6 Appendix 6: Organisational Structure and Responsibilities

Chief Investigator
The Chief Investigator has overall responsibility for:

(i) Design and conduct of the Study in collaboration with the Trial Steering Committee;
(ii) Preparation of the Protocol and subsequent revisions;

Trial Steering Committee
The Trial Steering Committee (see Section 0 for list of members) is responsible for:

(i) Agreement of the final Protocol and the Data Analysis Plans;
(ii) Reviewing progress of the study and, if necessary, deciding on Protocol changes;
(iii) Review and approval of study publications and substudy proposals;
(iv) Reviewing new studies that may be of relevance.

International Steering Committee
The internationalSteering Committee (see below for list of members) is responsible for:

(i) Reviewing progress of the study in sites outside the UK;
(ii) Review of study publications and substudy proposals;
(iii) Considering potential new therapies to be included in sites outside the UK;
(iv) Assisting RCC in selection of LCCs
(v) Reviewing new studies that may be of relevance.

Data Monitoring Committee
The independent Data Monitoring Committee is responsible for:

(i) Reviewing unblinded interim analyses according to the Protocol;
(ii) Advising the Steering Committee if, in their view, the randomised data provide evidence that may warrant a change in the protocol (e.g. modification or cessation of one or more of the treatment arms).

Central Coordinating Office (CCO)
The CCO is responsible for the overall coordination of the Study, including:

(i) Study planning and organisation of Steering Committee meetings;
(ii) Ensuring necessary regulatory and ethics committee approvals;
(iii) Development of Standard Operating Procedures and computer systems
(iv) Monitoring overall progress of the study;
(v) Provision of study materials to RCCs/LCCs;
(vi) Monitoring and reporting safety information in line with the protocol and regulatory requirements;
(vii) Dealing with technical, medical and administrative queries from LCCs.
Regional Coordinating Centre (RCC)
The RCCs are responsible for:

(i) Ensuring necessary regulatory and ethics committee approvals;
(ii) Provision of study materials to LCCs;
(iii) Dealing with technical, medical and administrative queries from LCCs.

Local Clinical Centres (LCC)
The LCC lead investigator and LCC clinic staff are responsible for:

(i) Obtaining all relevant local permissions (assisted by the CCO)
(ii) All trial activities at the LCC, including appropriate training and supervision for clinical staff
(iii) Conducting trial procedures at the LCC in line with all relevant local policies and procedures;
(iv) Dealing with enquiries from participants and others.

Organisational Details

STEERING COMMITTEE
(Major organisational and policy decisions, and scientific advice; blinded to treatment allocation)

Chief Investigator
Peter Horby
Deputy Chief Investigator
Martin Landray
Clinical Trial Unit Lead
Richard Haynes
Co-investigators
Kenneth Baillie (Scotland Lead), Maya Buch, Lucy Chappell, Saul Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Marion Mafham, Alan Montgomery, Andrew Mumford, Kathy Rowan, Guy Thwaites, Jeremy Day (South East Asia Leads)

International Steering Committee

Chair
Do Van Dung
Regional Lead Investigators
Guy Thwaites, Jeremy Day
Independent members:
Vietnam : Nguyen Ngo Quang, Prof. Binh
Indonesia: Erlina Burhan, Bachti Alisjahbana
Nepal: Janak Koirala, Sudha Basnet
Other members:
Evelyne Kestelyn, Buddha Basnyat, Pradip Gyanwali, Raph Hamers, John Amuasi, Peter Horby

DATA MONITORING COMMITTEE
(Interim analyses and response to specific concerns)

Chair
Peter Sandercock
Members
Janet Darbyshire, David DeMets, Robert Fowler, David Laloo, Mohammed Munavvar, Adilia Warris, Janet Wittes
Statisticians (non-voting)
Jonathan Emberson, Natalie Staplin
9 REFERENCES


10 CONTACT DETAILS

Website: www.recoverytrial.net
(copies of this protocol and related forms and information can be downloaded)

RECOVERY Central Coordinating Office:
Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF
United Kingdom
Tel: +44 (0)800 1385451
E-mail: recoverytrial@ndph.ox.ac.uk

RECOVERY Vietnam:
Oxford University Clinical Research Unit, Centre for Tropical Medicine, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam
Tel: +84 8 39241983
E-mail: recoverytrial@oucru.org

RECOVERY Indonesia:
Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology
Jl. P. Diponegoro No. 69, Jakarta-Indonesia 10430
Tel: +62 21 31900971

RECOVERY Nepal:
Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences,
Kathmandu, Nepal
Tel: +977 01 5522295

RECOVERY Ghana:
Kumasi Center for Collaborative Research in Tropical Medicine
KNUST, Southend Asuogya Road, GPS: AK-312-1059, Kumasi, Ghana
Tel: +233 278 364 389

RECOVERY South Africa
Wits Health Consortium, 31 Princess of Wales Terrace, Parktown, Johannesburg, South Africa
Tel: +27 11 274 9200

RECOVERY Sri Lanka & Pakistan
National Intensive Care Surveillance - M.O.R.U, 2nd Floor, YMBA Building, Borella, Colombo 08, Sri Lanka
Tel: +94 114 063739

RECOVERY India
Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, Ramalingaswami Bhavan, Ansari Nagar, ICMR-110029
Tel: +91 996 840 8999

To RANDOMISE a patient, visit:

Website: www.recoverytrial.net